BDSX (Biodesix) Net earnings per share (EPS TTM)

Biodesix, Inc. (BDSX) leads in comprehensive lung cancer diagnostics, leveraging AI for accelerated biomarker analysis. Net income per share over the last 12 months illustrates profit dynamics, where the -2.78 metric confirms the current level. Biodesix, Inc. (BDSX) implements tests through partnerships with clinics and pharmaceutical behemoths. A wide range of rapid diagnostics and insurance coverage enable the company to effectively expand its market share.

BDSX biodesix.com Earnings per share for the last twelve months (07/04/2022 - 11/15/2026)

Metric breakdowns and analytics for Biodesix Corp (BDSX)

- current quotes and average value forecast:

Price Chart Biodesix Corp|BDSX - Broker Consensus Forecast

- business market valuation indicators:

Market Capitalization Biodesix Inc|BDSX - Enterprise Value

- business book valuation details:

Net Assets per Single Share Biodesix|BDSX - Company Book Value|Market Cap to Net Assets Ratio biodesix.com|BDSX - Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

BDSX - Net Financial Result|Expected Profit Biodesix, Inc.|BDSX - Market Cap to Earnings|Forward P/E Multiple Biodesix, Inc.|BDSX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Biodesix, Inc.|BDSX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Biodesix|BDSX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth biodesix.com|BDSX - Expected net earnings per share growth this year|Expected earnings per share growth for next year Biodesix, Inc.

- sales and revenue indicators:

BDSX - Company Sales Volume|Company Future Sales Volume Biodesix|BDSX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Biodesix|BDSX - Annual Revenue Growth (Last Twelve Months)

Fundamental company analysis:BDSX - Biodesix Inc

The market assesses the potential of Biodesix, Inc. (BDSX) through the lens of the scalability of its diagnostic solutions. The EPS TTM metric measures the portion of net income attributable to each share over a year, excluding the impact of the total issuance volume. By analyzing this chart of net income per share over the last 12 months, an investor can see the real profitability of the business. Growth in this metric directly depends on the expansion of Medicare insurance coverage and the integration of tests into clinics. This asset belongs to the high-tech biomedical sector.

Competitors of Biodesix, Inc.